NASDAQ:ITCIIntra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ITCI shares have increased by 26.1% and is now trading at $22.41. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Intra-Cellular Therapies.

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Intra-Cellular Therapies.

Intra-Cellular Therapies Inc (NASDAQ:ITCI) posted its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.20. The biopharmaceutical company had revenue of $1.08 million for the quarter, compared to analyst estimates of $1.75 million. View Intra-Cellular Therapies' earnings history.

10 equities research analysts have issued 12 month price targets for Intra-Cellular Therapies' shares. Their forecasts range from $16.00 to $68.00. On average, they anticipate Intra-Cellular Therapies' share price to reach $37.13 in the next year. This suggests a possible upside of 65.7% from the stock's current price. View analysts' price targets for Intra-Cellular Therapies.

Media coverage about ITCI stock has been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a news impact score of -4.6 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news aboutIntra-Cellular Therapies.

Some companies that are related to Intra-Cellular Therapies include Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Mirati Therapeutics (MRTX), Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK) and ChemoCentryx (CCXI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Amarin (AMRN), Crispr Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Gilead Sciences (GILD), AbbVie (ABBV), Clovis Oncology (CLVS), Novavax (NVAX), Myovant Sciences (MYOV), ACADIA Pharmaceuticals (ACAD) and Karyopharm Therapeutics (KPTI).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.70%), Wasatch Advisors Inc. (4.43%), State Street Corp (1.86%), Samlyn Capital LLC (1.74%), Schroder Investment Management Group (1.68%) and St. Louis Trust Co (1.33%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View institutional ownership trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, JPMorgan Chase & Co., Voloridge Investment Management LLC, General American Investors Co. Inc., DCF Advisers LLC, CSS LLC IL, UBS Group AG, and Two Sigma Advisers LP. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, and Sharon Mates. View insider buying and selling activity for Intra-Cellular Therapies.

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Ikarian Capital LLC, Samlyn Capital LLC, St. Louis Trust Co, BlackRock Inc., Alyeska Investment Group L.P., Schroder Investment Management Group, and Invesco Ltd.. View insider buying and selling activity for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $22.41.

Intra-Cellular Therapies has a market capitalization of $1.49 billion and generates $60,000.00 in revenue each year. The biopharmaceutical company earns $-147,720,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]